Physician profile
Brian R Sponseller
NPI 1891984647
$14,646.45
in general payments reported to CMS, 2019-2025
70 companies · $1,709 in 2025
The $1,709 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,654 · 2020: $1,286 · 2021: $1,680 · 2022: $2,705 · 2023: $2,513 · 2024: $3,100 · 2025: $1,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,265 · Long Term Medical Supply Or Device Loan: $49.95 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,265.36 |
| Long Term Medical Supply Or Device Loan | $49.95 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,298.51 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $1,037.97 | 2019-2025 | |
| Novo Nordisk INC | $1,008.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $907.72 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $827.87 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $591.58 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Ironwood Pharmaceuticals, INC | $564.47 | 2019-2025 | Linzess |
| Amgen INC. | $530.07 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $456.38 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.49 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $430.55 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $345.70 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Supernus Pharmaceuticals, INC. | $328.51 | 2021-2024 | Qelbree, Xyosted, Tlando |
| Novartis Pharmaceuticals Corporation | $326.36 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $302.75 | 2022-2025 |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Sponseller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.